TRIGLYCERIDE-RICH LIPOPROTEINS AND ATHEROSCLEROSIS

被引:9
作者
SCHWANDT, P
机构
[1] Medical Department Ii, Klinikum Grosshadern, University of Munich, Munich
基金
美国国家卫生研究院;
关键词
D O I
10.2165/00003495-199000401-00009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although still the subject of debate, most investigators accept that plasma triglyceride levels are a risk factor for coronary heart disease. Data from epidemiological studies such as the Framingham Heart Study, the Paris Prospective Heart Study and the Stockholm Heart Study have shown that patients with elevated plasma triglyceride levels have a higher incidence of coronary heart disease. In one study, coronary heart disease mortality fell by 36% after continued lowering of plasma triglyceride levels. In patients whose triglyceride levels fell > 30%, mortality decreased by 60%. The effect of triglycerides as a risk factor appears to be obscured in studies that use multiple cardiac end-points. Several studies demonstrated a stronger association between plasma triglyceride levels and coronary heart disease in patients with total cholesterol levels < 5.7 mmol/L, or high density lipoprotein (HDL)-cholesterol levels < 1 mmol/L. Angiographic data have confirmed these findings and show clearly that elevated triglyceride levels are frequently observed in men with coronary heart disease. Other studies have demonstrated that remnants of triglyceride-rich lipoprotein particles are cytotoxic and atherogenic in vitro and in vivo. Also, patients with familial dysβ-lipoproteinaemia, a condition characterised by high levels of triglyceride-rich very low density lipoprotein (VLDL) particles, have a high risk of atherosclerosis. Thus, there seems to be evidence supporting the atherogenic properties of cholesterylester-rich particles, or remnants thereof. © 1990, Adis International Limited. All rights reserved.
引用
收藏
页码:38 / 41
页数:4
相关论文
共 14 条
[1]  
BARBIR M, 1988, BRIT HEART J, V60, P397
[2]  
BROWN MS, 1987, HARRISONS PRINCIPLES, P1650
[3]   IS THE LEVEL OF SERUM TRIGLYCERIDE A SIGNIFICANT PREDICTOR OF CORONARY DEATH IN NORMOCHOLESTEROLEMIC SUBJECTS - THE PARIS PROSPECTIVE-STUDY [J].
CAMBIEN, F ;
JACQUESON, A ;
RICHARD, JL ;
WARNET, JM ;
DUCIMETIERE, P ;
CLAUDE, JR .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1986, 124 (04) :624-632
[4]  
CARLSON LA, 1988, ACTA MED SCAND, V223, P405
[5]   THE TRIGLYCERIDE ISSUE - A VIEW FROM FRAMINGHAM [J].
CASTELLI, WP .
AMERICAN HEART JOURNAL, 1986, 112 (02) :432-437
[6]   LIPOLYTIC SURFACE REMNANTS OF TRIGLYCERIDE-RICH LIPOPROTEINS ARE CYTO-TOXIC TO MACROPHAGES BUT NOT IN THE PRESENCE OF HIGH-DENSITY LIPOPROTEIN - A POSSIBLE MECHANISM OF ATHEROGENESIS [J].
CHUNG, BH ;
SEGREST, JP ;
SMITH, K ;
GRIFFIN, FM ;
BROUILLETTE, CG .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (04) :1363-1374
[7]  
CRIQUI MH, 1988, ZEROING TRIGLYCERIDE
[8]   RELATION OF TRIGLYCERIDE LEVELS TO CORONARY-ARTERY DISEASE - THE MILWAUKEE CARDIOVASCULAR DATA REGISTRY [J].
FREEDMAN, DS ;
GRUCHOW, HW ;
ANDERSON, AJ ;
RIMM, AA ;
BARBORIAK, JJ .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1988, 127 (06) :1118-1130
[9]   HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE [J].
FRICK, MH ;
ELO, O ;
HAAPA, K ;
HEINONEN, OP ;
HEINSALMI, P ;
HELO, P ;
HUTTUNEN, JK ;
KAITANIEMI, P ;
KOSKINEN, P ;
MANNINEN, V ;
MAENPAA, H ;
MALKONEN, M ;
MANTTARI, M ;
NOROLA, S ;
PASTERNACK, A ;
PIKKARAINEN, J ;
ROMO, M ;
SJOBLOM, T ;
NIKKILA, EA .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) :1237-1245
[10]   ABNORMAL EFFECTS OF HYPER-TRIACYLGLYCEROLEMIC VERY LOW-DENSITY LIPOPROTEINS ON 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE-ACTIVITY AND VIABILITY OF CULTURED BOVINE AORTIC ENDOTHELIAL-CELLS [J].
GIANTURCO, SH ;
ESKIN, SG ;
NAVARRO, LT ;
LAHART, CJ ;
SMITH, LC ;
GOTTO, AM .
BIOCHIMICA ET BIOPHYSICA ACTA, 1980, 618 (01) :143-152